Clinical trial
AZD8330 First Time in Man in Patients With Advanced Malignancies
NCT00454090 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00454090 |
|---|---|
| Title | AZD8330 First Time in Man in Patients With Advanced Malignancies |
| Official title | A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | AZD8330 |
| Enrollment | 83 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2010 |
| Completion | Mar 1, 2011 |
| First posted | Mar 29, 2007 |
| Last update posted | Aug 24, 2011 |
| Countries | Norway, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: